NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

最近更新时间: 4小时之前

85.00

-18.44 (-17.83%)

  • 1天 -17.83%
  • 5天 -20.52%
  • 1月 -19.09%
  • 6月 -40.26%
  • 今年至今天 -16.76%
  • 1年 -17.24%
  • 5年 194.83%
前收盘价格 103.44
收盘价格 82.72
成交量 52,675,404
平均成交量 (3个月) 6,077,740
市值 363,606,212,608
市盈率 (P/E TTM) 28.52
预期市盈率 (P/E Forward) 26.39
价格/销量 (P/S) 12.14
股市价格/股市净资产 (P/B) 27.10
52周波幅
81.50 (-4%) — 148.15 (74%)
利润日期 5 Feb 2025
股息率 (DY TTM) 1.70%
营业毛利率 35.01%
营业利益率 (TTM) 47.43%
稀释每股收益 (EPS TTM) 2.98
季度收入增长率 (YOY) 21.40%
季度盈利增长率 (YOY) 21.50%
总债务/股东权益 (D/E MRQ) 47.27%
流动比率 (MRQ) 0.940
营业现金流 (OCF TTM) 118.22 B
杠杆自由现金流 (LFCF TTM) 46.04 B
资产报酬率 (ROA TTM) 21.47%
股东权益报酬率 (ROE TTM) 88.73%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 Novo Nordisk A/S 看跌 看涨

AIStockmoo 评分

1.4
分析师共识 3.0
内部交易活动 NA
价格波动 5.0
技术平均移动指标 0.0
技术振荡指标 -2.5
平均 1.38

相关股票

股票 市值 DY P/E（TTM） P/B
NVO 364 B 1.70% 28.52 27.10
ADCT 190 M - - -
BHVN 4 B - - 11.75
RCUS 1 B - - 2.46
DNA 579 M - - 0.780
NUVB 946 M - - 1.80

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
部门 Healthcare
行业 Biotechnology
投资方式 Large Growth
机构持股比例 10.16%

所有权

姓名 日期 持有股份
Fayez Sarofim & Co 30 Sep 2024 12,217,118
Folketrygdfondet 30 Sep 2024 8,863,625
Gqg Partners Llc 30 Sep 2024 7,438,073
Everett Harris & Co /Ca/ 30 Sep 2024 6,438,614
52周波幅
81.50 (-4%) — 148.15 (74%)
目标价格波幅
156.00 (83%) — 160.00 (88%)
高 160.00 (Cantor Fitzgerald, 88.24%) 购买
中 158.00 (85.88%)
低 156.00 (BMO Capital, 83.53%) 购买
平均值 158.00 (85.88%)
总计 2 购买
平均价格@调整类型 111.79
公司 日期 目标价格 调整类型 价格@调整类型
Cantor Fitzgerald 06 Nov 2024 160.00 (88.24%) 购买 105.36
10 Oct 2024 160.00 (88.24%) 购买 117.53
BMO Capital 17 Oct 2024 156.00 (83.53%) 购买 118.22
  • 3M
日期 类型 细节
20 Dec 2024 CNBC FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
20 Dec 2024 公告 Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
18 Dec 2024 公告 The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed
18 Dec 2024 CNBC Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
16 Dec 2024 公告 Novo Nordisk A/S - share repurchase programme
16 Dec 2024 公告 Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark
14 Dec 2024 公告 Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
12 Dec 2024 公告 Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events
11 Dec 2024 CNBC Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
09 Dec 2024 CNBC Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says
06 Dec 2024 公告 The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
04 Dec 2024 CNBC Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
03 Dec 2024 公告 Defiance Launches NVOX, the First 2X Leveraged Single-Stock ETF on Novo Nordisk
26 Nov 2024 CNBC Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
25 Nov 2024 公告 Novo Nordisk A/S - share repurchase programme
13 Nov 2024 CNBC Amgen says no concerns around weight loss drug’s bone density data after stock falls
08 Nov 2024 公告 Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
08 Nov 2024 公告 Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme
07 Nov 2024 公告 Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
06 Nov 2024 公告 Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024
05 Nov 2024 公告 Novo Nordisk A/S - share repurchase programme
01 Nov 2024 公告 Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
30 Oct 2024 CNBC Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
30 Oct 2024 CNBC Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
23 Oct 2024 CNBC Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
21 Oct 2024 公告 Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial
21 Oct 2024 公告 Novo Nordisk A/S - share repurchase programme
18 Oct 2024 公告 Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
08 Oct 2024 公告 Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities
07 Oct 2024 公告 Novo Nordisk A/S – Share repurchase programme
25 Sep 2024 CNBC Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
24 Sep 2024 CNBC 'Stop ripping us off': Senate grills Novo Nordisk CEO on weight loss drug pricing
显示更多
股息率 (DY TTM) 1.70%
5年平均股息收益率 2.99%
股息支付比率 46.73%
预计下次股息支付 Apr 2025
除息日 公告日期 支付日期 详情
16 Aug 2024 06 Aug 2024 26 Aug 2024 0.5126402 现金
22 Mar 2024 31 Jan 2024 02 Apr 2024 0.92985 现金
18 Aug 2023 10 Aug 2023 29 Aug 2023 0.8835613 现金
24 Mar 2023 02 Feb 2023 04 Apr 2023 1.1887415 现金
12 Aug 2022 04 Aug 2022 23 Aug 2022 0.5835507 现金
25 Mar 2022 02 Mar 2022 05 Apr 2022 1.022423 现金
16 Aug 2021 - 25 Aug 2021 0.5502889 现金
26 Mar 2021 - 07 Apr 2021 0.922122 现金
14 Aug 2020 06 Aug 2020 25 Aug 2020 0.5177774 现金
27 Mar 2020 06 Feb 2020 07 Apr 2020 0.7826048 现金
16 Aug 2019 10 Aug 2019 27 Aug 2019 0.449438 现金
22 Mar 2019 05 Feb 2019 02 Apr 2019 0.777006 现金
17 Aug 2018 09 Aug 2018 28 Aug 2018 0.462327 现金
23 Mar 2018 24 Mar 2018 03 Apr 2018 0.805982 现金
17 Aug 2017 - 29 Aug 2017 0.33589 现金
23 Mar 2017 - 04 Apr 2017 0.479369 现金
11 Aug 2016 - 23 Aug 2016 0.331026 现金
18 Mar 2016 - 30 Mar 2016 0.69943 现金
19 Mar 2015 - 31 Mar 2015 0.532885 现金
21 Mar 2014 - 02 Apr 2014 0.606122 现金
21 Mar 2013 - 02 Apr 2013 2.264307 现金
22 Mar 2012 - 03 Apr 2012 1.831902 现金
24 Mar 2011 - 05 Apr 2011 1.357901 现金
25 Mar 2010 - 07 Apr 2010 0.978615 现金
19 Mar 2009 - 31 Mar 2009 0.781532 现金
13 Mar 2008 - 25 Mar 2008 0.678462 现金
08 Mar 2007 - 20 Mar 2007 0.891779 现金
09 Mar 2006 - 21 Mar 2006 0.691753 现金
10 Mar 2005 - 22 Mar 2005 0.61725 现金
17 Mar 2004 - 29 Mar 2004 0.52096 现金
26 Mar 2003 - 07 Apr 2003 0.37647 现金
13 Mar 2002 - 25 Mar 2002 0.2848 现金
21 Mar 2001 - 02 Apr 2001 0.5681 现金
24 Mar 2000 - 06 Apr 2000 0.4672 现金
25 Mar 1999 - 06 Apr 1999 0.4182 现金
27 Mar 1998 - 08 Apr 1998 0.3051 现金
25 Apr 1997 - 07 May 1997 0.239 现金
01 May 1996 - 14 May 1996 0.1806 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2024 1.44 2 1.70
2023 2.07 2 2.00
2022 1.61 2 2.37
2021 1.47 2 2.63
2020 1.30 2 3.72
2019 1.23 2 4.24
2018 1.27 2 5.51
2017 0.815 2 3.04
2016 1.03 2 5.75
2015 0.533 1 1.84
2014 0.606 1 2.86
2013 2.26 1 12.26
2012 1.83 1 11.22
2011 1.36 1 11.78
2010 0.979 1 8.69
2009 0.782 1 12.24
2008 0.678 1 13.20
2007 0.892 1 13.75
2006 0.692 1 16.54
2005 0.617 1 21.94
2004 0.521 1 19.20
2003 0.376 1 18.38
2002 0.285 1 19.71
2001 0.568 1 28.33
2000 0.467 1 26.40
1999 0.418 1 32.36
1998 0.305 1 22.94
1997 0.239 1 16.57
1996 0.181 1 19.32
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2024 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票